Figure 2. Life years and QALYs gained (A) and cost-effectiveness (B) of lifetime statin therapy in categories by prior cardiovascular disease, sex and pre-treatment LDL cholesterol level. Incremental Cost-Effectiveness Ratio (ICER) is the ratio of the incremental costs divided by the incremental QALYs with costs and QALYs discounted at 3.5% per year. CVD, cardiovascular disease; LDL, low density lipoprotein; QALY, quality-adjusted life years.